Nanotechnology Drug and Gene Delivery
Note: This page is educational. Nanocarriers are regulated medical products, not generic "nano supplements" or do-it-yourself delivery systems.
TL;DR
Nanotechnology delivery uses nanoscale carriers to move a payload through the body, protect it from degradation, tune pharmacokinetics, and sometimes trigger release in a chosen tissue or microenvironment. In oncology, the most clinically mature examples are liposomal and albumin-bound chemotherapies. RNA and gene delivery are powerful but harder: the carrier must protect the nucleic acid, reach the right cells, escape endosomes, express or silence the target, and avoid unacceptable immune toxicity. Sources: [1], [2], [3]
1. What is being delivered?
| Payload | Examples | Main challenge |
|---|---|---|
| Small-molecule drug | doxorubicin, irinotecan, paclitaxel | solubility, toxicity, distribution |
| Protein or peptide | cytokines, enzymes, antigens | stability, immunogenicity |
| siRNA / miRNA | gene silencing | endosomal escape, off-target effects |
| mRNA | antigen, cytokine, CAR/TCR component | cell targeting, expression window, innate sensing |
| DNA / plasmid | gene expression or editing cargo | nuclear entry, duration, safety |
| Imaging agent | iron oxide, gadolinium, fluorophores | signal, clearance, toxicity |
| Combination payload | drug + imaging, drug + heat, drug + photosensitizer | manufacturing and attribution of effect |
2. Carrier families
| Carrier | Strength | Weakness |
|---|---|---|
| Liposomes | clinically proven, tunable, drug encapsulation | leakage, RES clearance, infusion reactions |
| Lipid nanoparticles (LNPs) | strong nucleic-acid delivery platform | liver tropism, immune activation, tumor targeting |
| Polymeric nanoparticles | tunable degradation and release | manufacturing complexity |
| Albumin particles | solvent-free drug formulation, biologic familiarity | not automatically tumor-specific |
| Inorganic particles | imaging, heat, radiation, optical properties | persistence and long-term safety questions |
| Exosomes / biomimetic vesicles | biological compatibility hypotheses | heterogeneity, scalability, cargo control |
| Antibody or ligand conjugates | target-aware delivery | antigen heterogeneity and off-tumor binding |
3. Passive vs active targeting
Passive targeting usually refers to altered tumor vasculature, poor lymphatic drainage, and longer circulation. It can help, but it is variable across patients and lesions.
Active targeting adds a ligand, antibody, peptide, aptamer, or sugar to bind a receptor. It can improve cell association, but it does not automatically solve vascular access, tissue penetration, endosomal escape, or toxicity.
Good delivery is a chain. Breaking one link can make the whole formulation fail.
4. The delivery chain
- Survive formulation, storage, and infusion.
- Avoid immediate aggregation or complement activation.
- Circulate long enough to reach relevant tissue.
- Exit vasculature or access the target compartment.
- Penetrate tissue beyond the first cell layers.
- Bind or enter the intended cell type.
- Release payload in the right cellular compartment.
- Produce a measurable pharmacodynamic effect.
- Clear or biodegrade safely.
Each step should have an assay. A tumor response without biodistribution data is hard to interpret; biodistribution without pharmacodynamics is also incomplete.
5. Oncology use cases
| Use case | Example question |
|---|---|
| Reduce toxicity | Can formulation lower cardiotoxicity, hypersensitivity, or marrow exposure? |
| Improve exposure | Can tumor AUC rise without increasing normal tissue AUC? |
| Enable insoluble drugs | Can the carrier make an otherwise unusable compound injectable? |
| Deliver RNA | Can mRNA encode tumor antigens or immune modulators? |
| Local release | Can pH, enzyme, light, heat, or radiation trigger payload release? |
| Theranostics | Can imaging confirm delivery before therapy is activated? |
6. What to measure
Minimum useful data:
- particle size distribution and polydispersity
- zeta potential or surface chemistry
- payload loading and release kinetics
- sterility and endotoxin
- complement activation
- plasma stability
- biodistribution
- tumor penetration
- cellular uptake
- endosomal escape, when relevant
- pharmacodynamic target engagement
- toxicity by organ
- batch reproducibility
7. What technologists can build
- Formulation-to-outcome databases connecting particle properties with PK, toxicity, and response.
- Image pipelines for IVIS, MRI, PET/SPECT, histology, and spatial distribution.
- Release-model simulators for pH, enzyme, heat, and light triggers.
- RNA delivery dashboards tracking expression, innate sensing, and cell-type specificity.
- Manufacturing QC systems with batch comparability and stability trends.
- Trial matching for patients with accessible lesions or delivery-relevant biomarkers.
See also
- Nanotherapeutics in cancer
- Photodynamic therapy advances
- Magnetic hyperthermia
- Biologics 101
- AI-driven drug discovery
References
- Chen J, Hu S, Sun M, et al. Recent advances and clinical translation of liposomal delivery systems in cancer therapy. Eur J Pharm Sci 2024;193:106688. PMID 38171420. https://doi.org/10.1016/j.ejps.2023.106688
- Wang-Gillam A, Hubner RA, Siveke JT, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer. Eur J Cancer 2019;108:78-87. PMID 30654298. https://doi.org/10.1016/j.ejca.2018.12.007
- Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with standard paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803. PMID 16172456. https://doi.org/10.1200/JCO.2005.04.937